Holen Sie sich die Stockscreener-App
16.95
0.71%
0.12
Schlusskurs vom Vortag:
$16.83
Offen:
$16.73
24-Stunden-Volumen:
8.09M
Relative Volume:
2.58
Marktkapitalisierung:
$2.28B
Einnahmen:
$66.50M
Nettoeinkommen (Verlust:
$-100.52M
KGV:
-18.49
EPS:
-0.9165
Netto-Cashflow:
$-146.77M
1W Leistung:
+52.15%
1M Leistung:
+35.49%
6M Leistung:
+144.24%
1J Leistung:
+703.32%
1-Tages-Spanne:
$16.00
$17.63
1-Wochen-Bereich:
$10.80
$17.63
52-Wochen-Spanne:
$1.03
$17.63
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
16.95 | 2.27B | 66.50M | -100.52M | -146.77M | -0.9165 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish - Insider Monkey
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Bitget
Jefferies raises Tango Therapeutics stock price target on RAS deal - Investing.com
Best Biotech Stocks To Add to Your WatchlistMarch 5th - MarketBeat
Assessing Tango Therapeutics (TNGX) Valuation After Earnings Update And New Erasca Trial Collaboration - simplywall.st
Tango rises on Q4 results, Erasca clinical pact (TNGX:NASDAQ) - Seeking Alpha
Tango Therapeutics Shares Rise After Q4 Loss Narrows - marketscreener.com
Tango Therapeutics stock hits 52-week high at $13.66 - Investing.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Stifel reiterates Tango Therapeutics stock Buy rating at $15 - Investing.com
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat - Bitget
Tango Therapeutics stock hits 52-week high at $13.66 By Investing.com - Investing.com India
Tango Therapeutics Hits Day High with Strong 7.39% Intraday Surge - Markets Mojo
Tango Therapeutics Reports Net Loss for 2025 and Updates on Clinical Pipeline Progress - geneonline.com
Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy - marketscreener.com
Earnings Flash (TNGX) Tango Therapeutics Posts Q4 Loss $0.29 a Share - marketscreener.com
Tango Therapeutics 2025 10-K: $62.4M Revenue, $(101.6)M Net Loss - TradingView
Tango Therapeutics Q4 net loss widens - TradingView
TNGX: Vopimetostat trials progress, cash runway extends to 2028, and leadership transitions completed - TradingView
Tango Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Erasca, Tango test dual-drug attack on tough pancreatic, lung cancers - Stock Titan
Pancreatic cancer bet: Tango sets 2026 pivotal trial with $343M war chest - Stock Titan
Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Investment Magazine
Earnings To Watch: Tango Therapeutics Inc (TNGX) Reports Q4 2025 Result - GuruFocus
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing - The Motley Fool
Biopharmaceutical company Erasca, Inc. (NASDAQ: ERAS) and Tango Therapeutics Inc. (NASDAQ: TNGX) announced a clinical collaboration to jointly conduct clinical evaluation of the combination therapy of ERAS-0015 and vopimetostat. - Bitget
TD Cowen Health Care Conference - marketscreener.com
Examining the Future: Tango Therapeutics's Earnings Outlook - Benzinga
TNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Tango Therapeutics Stock Hits Day Low of $10.90 Amid Price Pressure - Markets Mojo
Barclays Global Healthcare Conference - marketscreener.com
Leerink Partners Global Healthcare Conference - marketscreener.com
Insider Sell Alert: Adam Crystal Sells Shares of Tango Therapeutics Inc (TNGX) - GuruFocus
Adam Crystal Sells 54,345 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Officer Sells Shares - TradingView
Tango Therapeutics (TNGX) R&D president sells 54,345 company shares - Stock Titan
Investment Review: Can Tango Therapeutics Inc be recession proofMarket Volume Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Stifel reiterates Tango Therapeutics stock rating at Buy By Investing.com - Investing.com South Africa
Stifel reiterates Tango Therapeutics stock rating at Buy - Investing.com Australia
Tango Therapeutics (NASDAQ:TNGX) Trading Down 10.4%Here's What Happened - MarketBeat
Adam Crystal sells 18,452 shares; Form 144 lists 54,345 RSUs (TNGX) - Stock Titan
Tango Therapeutics (TNGX) Price Target Increased by 11.32% to 15.19 - Nasdaq
Tango Therapeutics Hits New 52-Week High of $13.60, Up 77.79% - Markets Mojo
Tango Therapeutics Achieves 423.87% Return, Emerges as a Multibagger Stock in Biotechnology Sector - Markets Mojo
Investment Report: Is Tango Therapeutics Inc in a long term uptrendJuly 2025 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Hits New 1-Year HighHere's Why - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Now Covered by Mizuho - Defense World
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.8%Should You Buy? - MarketBeat
Mizuho Initiates Coverage of Tango Therapeutics (TNGX) with Outperform Recommendation - Nasdaq
Tango Therapeutics stock hits 52-week high at 13.5 USD - Investing.com
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
2.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):